Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZYG
|
|||
| Former ID |
DAP000385
|
|||
| Drug Name |
Alemtuzumab
|
|||
| Synonyms |
Campath (TN); MabCampath (TN); Campath-1H (TN)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Approved | [1], [2], [3] | |
| Multiple sclerosis [ICD-11: 8A40] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bayer Schering Pharma
|
|||
| ADReCS Drug ID | BADD_D00064 | |||
| SuperDrug ATC ID |
L01XC04
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cambridge pathology 1 antigen (CD52) | Target Info | . | [4], [5], [6], [7] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6770). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | |||
| REF 4 | Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49. | |||
| REF 5 | Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation. Ann Transplant. 2009 Apr-Jun;14(2):7-12. | |||
| REF 6 | CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma. 2009 Jun;50(6):1010-6. | |||
| REF 7 | Targeted therapy for chronic lymphocytic leukemia. Target Oncol. 2009 Jan;4(1):11-21. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.